Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Thrombosis and Haemostasis|October 16, 2015
Dabigatran treatment simulation in patients undergoing maintenance haemodialysisKarl-Heinz Liesenfeld, Andreas Clemens, Joerg Kreuzer, et al.Diabetes|March 2, 2002
The proline 12 alanine substitution in the peroxisome proliferator--activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivoJochen Schneider, Joerg Kreuzer, Andreas Hamann, et al.Atherosclerosis|June 6, 2002
Activity and concentration of lipoprotein lipase in post-heparin plasma and the extent of coronary artery diseaseKlaus A Dugi, Nikolaus Schmidt, Karin Brandauer, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|September 23, 2006
Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient miceFlorian Bea, Joerg Kreuzer, Michael Preusch, et al.Thrombosis and Haemostasis|July 15, 2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER IISamuel Z Goldhaber, Sebastian Schellong, Ajay Kakkar, et al.Pacing and Clinical Electrophysiology : PACE|January 12, 2013
Are plasma natriuretic peptide levels influenced by automatic pacemaker algorithms for ventricular pacing minimization?Joerg Kreuzer, Carsten Lennerz, Josef U Dietl, et al.Vascular Medicine (London, England)|November 4, 2016
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™Samuel Z Goldhaber, Henry Eriksson, Ajay Kakkar, et al.Journal of Cardiovascular Pharmacology|August 19, 2007
Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient miceMichael R Preusch, Florian Bea, Sara H Yang, et al.Diabetes Care|November 25, 2004
Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistanceMaximilian von Eynatten, Jochen G Schneider, Per M Humpert, et al.The American Journal of Pathology|November 5, 2002
Immunosuppressive treatment protects against angiotensin II-induced renal damageDominik N Muller, Erdenechimeg Shagdarsuren, Joon-Keun Park, et al.Pageof 2